Evidence map›Paper›PMID 27220617›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2016

Low-Affinity Neurotrophin Receptor p75 Promotes the Transduction of Targeted Lentiviral Vectors to Cholinergic Neurons of Rat Basal Forebrain.

Inga Antyborzec, Valerie B O'Leary, James O Dolly, Saak V Ovsepian

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Alleviation of Trigeminal Nociception Using p75 Neurotrophin Receptor Targeted Lentiviral Interference Therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Inga AntyborzecInternational Centre for Neurotherapeutics, Dublin City University, Dublin, Ireland.
Valerie B O'LearyInternational Centre for Neurotherapeutics, Dublin City University, Dublin, Ireland.
James O DollyInternational Centre for Neurotherapeutics, Dublin City University, Dublin, Ireland.
Saak V OvsepianInternational Centre for Neurotherapeutics, Dublin City University, Dublin, Ireland. saak.ovsepian@gmail.com.
Dublin City University · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Basal forebrain cholinergic neurons (BFCNs) are one of the most affected neuronal types in Alzheimer's disease (AD), with their extensive loss documented at late stages of the pathology. While discriminatory provision of neuroprotective agents and trophic factors to these cells is thought to be of substantial therapeutic potential, the intricate topography and structure of the forebrain cholinergic system imposes a major challenge. To overcome this, we took advantage of the physiological enrichment of BFCNs with a low-affinity p75 neurotrophin receptor (p75

Indexed as

Transduction, GeneticAction PotentialsAnimalsBasal ForebrainCholine O-AcetyltransferaseCholinergic NeuronsFemaleGenetic VectorsGreen Fluorescent ProteinsHEK293 CellsHumansInjections, IntraventricularIn Vitro TechniquesLentivirusMaleMicroscopy, ConfocalCholine O-AcetyltransferaseGreen Fluorescent ProteinsReceptor, Nerve Growth FactorAlzheimer’s diseaseBasal forebrain cholinergic neuronsGene therapyNeuroprotectionp75 neurotrophin receptorStreptavidin–biotin

Identifiers

PMID27220617
PMCPMC5081123
OpenAlexW2399448042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.